Loading…

Optimizing ultrafast dynamic contrast-enhanced MRI scan duration in the differentiation of benign and malignant breast lesions

Objective To determine the optimal scan duration for ultrafast DCE-MRI in effectively differentiating benign from malignant breast lesions. Methods The study prospectively recruited participants who underwent breast ultrafast DCE-MRI from September 2021 to March 2023. A 30-phase breast ultrafast DCE...

Full description

Saved in:
Bibliographic Details
Published in:Insights into imaging 2024-05, Vol.15 (1), p.112-112, Article 112
Main Authors: Cao, Ying, Huang, Yao, Chen, Xianglong, Wang, Wei, Chen, Huifang, Yin, Ting, Nickel, Dominik, Li, Changchun, Shao, Junhua, Zhang, Shi, Wang, Xiaoxia, Zhang, Jiuquan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To determine the optimal scan duration for ultrafast DCE-MRI in effectively differentiating benign from malignant breast lesions. Methods The study prospectively recruited participants who underwent breast ultrafast DCE-MRI from September 2021 to March 2023. A 30-phase breast ultrafast DCE-MRI on a 3.0-T MRI system was conducted with a 4.5-s temporal resolution. Scan durations ranged from 40.5 s to 135.0 s, during which the analysis is performed at three-phase intervals, forming eight dynamic sets (scan duration [SD] 40.5s : 40.5 s, SD 54s : 54.0 s, SD 67.5s : 67.5 s, SD 81s : 81.0 s, SD 94.5s : 94.5 s, SD 108s : 108.0 s, SD 121.5s : 121.5 s, and SD 135s : 135.0 s). Two ultrafast DCE-MRI parameters, maximum slope (MS) and initial area under the curve in 60 s (iAUC), were calculated for each dynamic set and compared between benign and malignant lesions. Areas under the receiver operating characteristic curve (AUCs) were used to assess their diagnostic performance. Results A total of 140 women (mean age, 47 ± 11 years) with 151 lesions were included. MS and iAUC from eight dynamic sets exhibited significant differences between benign and malignant lesions (all p  
ISSN:1869-4101
1869-4101
DOI:10.1186/s13244-024-01697-6